GUILLERMO
LÓPEZ VIVANCO
Researcher to 2022
Complejo Asistencial Universitario de Burgos
Burgos, EspañaPublications in collaboration with researchers from Complejo Asistencial Universitario de Burgos (6)
2022
2021
-
Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
Cancer Chemotherapy and Pharmacology, Vol. 87, Núm. 4, pp. 543-553
2018
-
Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS
Clinical and Translational Oncology, Vol. 20, Núm. 10, pp. 1261-1267
2016
-
147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study
Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. S122
2012
-
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: A randomised phase II study
British Journal of Cancer, Vol. 107, Núm. 3, pp. 435-441
2006
-
Irinotecan (CPT-11) combined with bolus 5-fluorouracil/leucovorin (Saltz regimen) as first-line chemotherapy of patients with advanced colorectal cancer
Anti-Cancer Drugs, Vol. 17, Núm. 1, pp. 89-94